Floatz logo

Irinotecan Sucrosofate

Metastatic Gastroesophageal Junction Adenocarcinoma

Academic and Community Cancer Research UnitedSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

113 Active assets in the Metastatic Gastroesophageal Junction Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
AstraZeneca
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 3BB
Eloxatin
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Irinotecan Sucrosofate is also rated in:

pancreatic adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →
malignant pancreatic neoplasmDormant
B
Indicative ·
62 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →